[144] Apellis Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Apellis Pharmaceuticals reported a Form 144 notice for a proposed sale of 32,729 shares of common stock through Fidelity Brokerage Services LLC with an aggregate market value of $911,829.94. The filing lists the approximate date of sale as 09/08/2025 and identifies the shares outstanding as 126,289,910. The notice discloses recent acquisitions of the shares: multiple restricted stock vesting events in January 2025 totaling 17,729 shares and an option-related item of 15,000 shares listed with a 09/08/2025 payment date described as Cash.

The filer certifies no undisclosed material adverse information and provides no reportable sales in the past three months. The form presents the broker, quantities, acquisition dates, nature of acquisition, and payment type but does not include the seller’s identity or reasons for sale.

Positive

• Complete transaction details provided including broker, share counts, acquisition dates, and payment type
• Affirmation of no undisclosed material adverse information included as required by Rule 144

Negative

• No identification of the selling person's name is provided in the visible content
• Filing does not state a 10b5-1 plan adoption date or trading plan details, so intent is not disclosed

Insights

Securities Analyst

TL;DR: Routine insider sale notice describing a modest block of shares derived from recent vesting and an option cash payment; appears procedural.

The Form 144 details a proposed sale of 32,729 common shares via Fidelity with an aggregate market value of $911,829.94 and identifies the acquisition sources as restricted stock vestings in January 2025 and a 15,000-share option-related item listed with a cash payment date of 09/08/2025. The filing states no sales in the past three months and includes the required representation about material nonpublic information. As a disclosure document, it supplies transaction timing and mechanics but contains no operational or financial performance data to alter valuation assumptions.

Corporate Governance Expert

TL;DR: Compliance-focused filing showing insider liquidity activity from compensation-related equity; governance disclosure requirements appear met.

The notice provides the broker name, exact share counts, acquisition dates, and nature of acquisition (restricted stock vesting and option-related), fulfilling Rule 144 reporting elements. The signer affirms absence of undisclosed material adverse information and there are no reported sales in the prior three months. The filing does not explain the purpose of the sale or identify any trading plan date, so stakeholders have disclosure of the transaction mechanics but not the seller’s intent.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	32729	911829.94	126289910	09/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/12/2025	Restricted Stock Vesting	Issuer			4663	01/12/2025	Compensation
Common	01/16/2025	Restricted Stock Vesting	Issuer			4207	01/16/2025	Compensation
Common	01/21/2025	Restricted Stock Vesting	Issuer			7530	01/21/2025	Compensation
Common	01/28/2025	Restricted Stock Vesting	Issuer			1329	01/28/2025	Compensation
Common	09/08/2025	Option Granted - 10/18/2017	Issuer			15000	09/08/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Apellis's Form 144 filed for APLS report?

The Form 144 reports a proposed sale of 32,729 common shares through Fidelity with an aggregate market value of $911,829.94, approximate sale date 09/08/2025.

How were the shares acquired that are listed in the Form 144?

The shares were acquired via multiple restricted stock vesting events in January 2025 (totaling 17,729 shares) and an option-related item of 15,000 shares with payment described as Cash on 09/08/2025.

Does the filing indicate any sales of Apellis stock in the past three months?

No. The filing states Nothing to Report under securities sold during the past three months.

Which broker is handling the proposed sale in the Form 144?

The broker named is Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI.

Does the Form 144 include a representation about material nonpublic information?

Yes. The filing includes the signer's representation that they do not know any material adverse information about the issuer that has not been publicly disclosed.